“Drug‐Carrier” Synergy Therapy for Amyloid‐β Clearance and Inhibition of Tau Phosphorylation via Biomimetic Lipid Nanocomposite Assembly

Amyloid‐β (Aβ) toxicity is considered to be companioned by Tau phosphorylation in Alzheimer's disease (AD). The clinical AD therapy is usually subjected to low blood‐brain barrier (BBB) penetration and complex interaction mechanisms between Aβ and phosphorylated Tau. A “Drug‐Carrier” synergy th...

Descripción completa

Detalles Bibliográficos
Autores principales: Han, Guochen, Bai, Kaiwen, Yang, Xiaoyu, Sun, Chenhua, Ji, Yi, Zhou, Jianping, Zhang, Huaqing, Ding, Yang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9108666/
https://www.ncbi.nlm.nih.gov/pubmed/35307993
http://dx.doi.org/10.1002/advs.202106072

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9108666/
https://www.ncbi.nlm.nih.gov/pubmed/35307993
http://dx.doi.org/10.1002/advs.202106072

Ejemplares similares